Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Langenberg

Vascular Surgery Evansville, IN Medical Doctor

NPI 1407845159 CMS profile 200093

520 Mary St, Ste 520, Evansville, IN 47710

Open in the dashboard

General payments

$35,966

463 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Langenberg of Evansville, IN is reported in the CMS Open Payments database as having received $35,966 across 463 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,475 98
2024 General $3,420 62
2023 General $2,076 40
2022 General $1,910 48
2021 General $3,626 95
2020 General $1,417 40
2019 General $4,043 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Langenberg
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Matthew Langenberg were reported at $19,475. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Matthew Langenberg Vascular Surgery median Middle half National median
2019 $4,043 $796 $226–$2,363 $163
2020 $1,417 $348 $118–$1,110 $114
2021 $3,626 $471 $158–$1,421 $132
2022 $1,910 $725 $222–$2,183 $149
2023 $2,076 $836 $257–$2,440 $160
2024 $3,420 $909 $252–$2,619 $164
2025 $19,475 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bard Peripheral Vascular, Inc. $14,718 54 payments
  2. Abbott Laboratories $4,730 49 payments
  3. Medtronic, Inc. $3,118 66 payments
  4. Endologix, Inc. $2,635 35 payments
  5. Silk Road Medical, Inc. $1,503 12 payments
  6. Inari Medical, Inc. $1,349 31 payments
  7. Medtronic Vascular, Inc. $1,283 31 payments
  8. TissueTech, Inc. $1,003 10 payments
  9. Janssen Pharmaceuticals, Inc $744 33 payments
  10. Penumbra, Inc. $685 7 payments
  11. Other $4,200 135 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,519 446 payments
  2. Consulting Fee $11,272 4 payments
  3. Travel and Lodging $4,086 12 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $89 1 payment
Products named General payments · program years 2019–2025
  1. PERCLOSE PROGLIDE $2,599 11 payments
  2. FLOWTRIEVER CATHETER, S $2,337 51 payments
  3. RotarexS 6 F x 135 cm $1,732 19 payments
  4. ENROUTE 0.014 Guidewire $1,216 7 payments
  5. ENROUTE Transcarotid Stent System $1,216 7 payments
  6. ENROUTE Transcarotid Neuroprotection System $1,216 7 payments
  7. ENHANCE Transcarotid Peripheral Access Kit $1,216 7 payments
  8. ENDURANT IIS $1,172 17 payments
  9. Alto Abdominal Stent Graft System $928 13 payments
  10. ESPRIT $817 8 payments
  11. Other $15,938 393 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

224

Median for Vascular Surgery: 122

Drug cost

$23,680

Median for Vascular Surgery: $14,135

Branded share of claims

59.4%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 12 $12,133
Eliquis Apixaban Brand 14 $9,283
Clopidogrel Clopidogrel Bisulfate Brand 107 $1,301
Atorvastatin Calcium Generic 62 $673
Rosuvastatin Calcium Generic 14 $225
Oxycodone Hcl Generic 15 $64

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 114 billing codes

Paid by Medicare

$128,645

Medicare's payments for the services billed

Medicare patients

671

Average age 76

Services billed

1,403

322 women, 349 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Diabetes 41%
Chronic kidney disease 41%
Ischemic heart disease 39%
Heart failure 33%
Atrial fibrillation 32%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

463 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record